Your browser is no longer supported. Please, upgrade your browser.
Omnicell, Inc.
Index- P/E124.31 EPS (ttm)1.31 Insider Own1.40% Shs Outstand43.26M Perf Week3.20%
Market Cap7.09B Forward P/E39.52 EPS next Y4.13 Insider Trans-17.14% Shs Float42.92M Perf Month5.77%
Income59.70M PEG8.29 EPS next Q0.91 Inst Own- Short Float6.24% Perf Quarter7.81%
Sales987.50M P/S7.17 EPS this Y-48.50% Inst Trans0.02% Short Ratio10.60 Perf Half Y19.89%
Book/sh24.33 P/B6.70 EPS next Y10.70% ROA3.20% Target Price166.80 Perf Year104.90%
Cash/sh14.38 P/C11.34 EPS next 5Y15.00% ROE6.00% 52W Range78.13 - 164.00 Perf YTD35.89%
Dividend- P/FCF31.97 EPS past 5Y-2.60% ROI2.70% 52W High-0.55% Beta1.01
Dividend %- Quick Ratio2.80 Sales past 5Y13.00% Gross Margin48.50% 52W Low108.75% ATR4.75
Employees2860 Current Ratio3.10 Sales Q/Q36.60% Oper. Margin8.00% RSI (14)61.30 Volatility3.11% 3.04%
OptionableYes Debt/Eq0.45 EPS Q/Q530.20% Profit Margin6.00% Rel Volume2.04 Prev Close163.20
ShortableYes LT Debt/Eq0.45 EarningsNov 02 BMO Payout0.00% Avg Volume252.45K Price163.10
Recom2.00 SMA204.47% SMA504.66% SMA20015.27% Volume504,827 Change-0.06%
Jun-09-21Initiated JP Morgan Neutral $146
May-24-21Initiated BTIG Research Buy $165
Feb-02-21Upgrade Piper Sandler Neutral → Overweight $86 → $147
Dec-08-20Initiated Berenberg Buy $145
Dec-03-20Downgrade Cantor Fitzgerald Overweight → Neutral $95
Jul-07-20Initiated Stephens Overweight $90
Feb-07-20Reiterated Dougherty & Company Buy $92 → $100
Nov-21-19Reiterated Dougherty & Company Buy $90 → $92
Jul-26-19Upgrade Craig Hallum Hold → Buy $85
Mar-07-19Reiterated Dougherty & Company Buy $78 → $90
Jun-29-18Resumed The Benchmark Company Buy $63
Sep-05-17Reiterated The Benchmark Company Buy $55 → $67
Jul-28-17Reiterated Dougherty & Company Buy $45 → $49
Apr-21-17Downgrade Piper Jaffray Overweight → Neutral
Jan-19-17Initiated Dougherty & Company Buy $44
Dec-06-16Reiterated The Benchmark Company Buy $39 → $55
Jul-07-16Reiterated FBR Capital Outperform $35 → $40
Mar-21-16Reiterated Topeka Capital Markets Buy $38 → $37
Jan-07-16Initiated The Benchmark Company Buy $33
Nov-16-15Reiterated Topeka Capital Markets Buy $40 → $38
Oct-14-21 11:40AM  
Oct-11-21 04:01PM  
Oct-08-21 06:45AM  
Oct-06-21 10:12AM  
Oct-05-21 06:20AM  
Oct-04-21 01:20PM  
Oct-01-21 11:09AM  
Sep-28-21 12:45PM  
Sep-24-21 10:45AM  
Sep-15-21 01:25PM  
Sep-13-21 10:33AM  
Sep-09-21 04:11PM  
Sep-07-21 09:16AM  
Sep-06-21 11:27PM  
Sep-01-21 10:35AM  
Aug-25-21 10:59AM  
Aug-24-21 11:40AM  
Aug-23-21 12:45PM  
Aug-18-21 04:31PM  
Aug-13-21 10:02AM  
Aug-09-21 09:49AM  
Aug-06-21 12:45PM  
Aug-02-21 08:19AM  
Jul-31-21 08:30AM  
Jul-30-21 10:24AM  
Jul-29-21 09:25AM  
Jul-26-21 11:30AM  
Jul-22-21 03:03PM  
Jul-20-21 10:42PM  
Jul-14-21 06:20AM  
Jul-12-21 08:31AM  
Jul-09-21 07:33AM  
Jul-08-21 11:40AM  
Jul-07-21 08:00AM  
Jul-01-21 05:12AM  
Jun-25-21 08:00AM  
Jun-22-21 11:40AM  
Jun-21-21 04:29PM  
Jun-03-21 11:40AM  
May-19-21 06:20AM  
May-18-21 11:40AM  
May-02-21 03:47AM  
Apr-30-21 10:29AM  
Apr-29-21 05:35PM  
Apr-28-21 04:29AM  
Apr-27-21 08:01AM  
Apr-22-21 12:33PM  
Apr-15-21 08:00AM  
Apr-12-21 08:23AM  
Apr-08-21 07:56AM  
Apr-07-21 08:01AM  
Apr-05-21 09:37AM  
Apr-01-21 04:05PM  
Mar-29-21 06:59AM  
Mar-15-21 04:26PM  
Mar-12-21 07:37AM  
Mar-08-21 11:00AM  
Mar-03-21 11:30AM  
Mar-02-21 10:11AM  
Feb-26-21 03:35AM  
Feb-22-21 08:30AM  
Feb-12-21 04:01PM  
Feb-02-21 08:35AM  
Feb-01-21 09:00PM  
Jan-29-21 05:57AM  
Jan-28-21 10:40AM  
Jan-27-21 10:42AM  
Jan-26-21 04:01PM  
Jan-25-21 12:30PM  
Jan-22-21 12:13PM  
Jan-19-21 09:52AM  
Jan-18-21 12:45PM  
Jan-15-21 08:51AM  
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Judson James TDirectorAug 23Sale153.004,984762,55118,336Aug 23 07:06 PM
Seim Robin GeneDirectorAug 09Sale151.606,6861,013,58630,049Aug 10 05:33 PM
JOHNSTON DAN SEVP & Chief Legal & AdminAug 06Option Exercise0.005,094033,823Aug 06 07:48 PM
Kuipers Peter J.Executive V P& CFOAug 06Option Exercise0.005,640065,452Aug 06 07:49 PM
JOHNSTON DAN SEVP & Chief Legal & AdminAug 06Sale160.005,094815,04028,729Aug 06 07:48 PM
Kuipers Peter J.Executive V P& CFOAug 06Sale157.8811,5001,815,63653,130Aug 06 07:49 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerAug 05Option Exercise0.0038,250082,267Aug 06 05:48 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerAug 05Sale153.0541,8786,409,29140,389Aug 06 05:48 PM
Kuipers Peter J.Executive V P& CFOAug 02Option Exercise0.0015,587081,909Aug 03 04:21 PM
Kuipers Peter J.Executive V P& CFOAug 02Sale146.1122,0973,228,61959,812Aug 03 04:21 PM
JOHNSTON DAN SEVP & Chief Legal & AdminJul 20Option Exercise0.0024,489059,965Jul 21 04:29 PM
JOHNSTON DAN SEVP & Chief Legal & AdminJul 20Sale151.3531,2364,727,70728,729Jul 21 04:29 PM
Kuipers Peter J.Executive V P& CFOMay 18Sale135.532,395324,59969,454May 18 05:09 PM
MELLON CHRISTINE MARIEEVP, Chief People OfficerMay 04Buy137.64435,91914,510May 05 11:16 AM
Seim Robin GeneDirectorJan 04Sale119.621,319157,77935,558Jan 04 05:18 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerDec 16Sale115.482,125245,39527,048Dec 17 04:16 PM
LIPPS RANDALL AChairman, President and CEODec 09Option Exercise0.0025,0000177,116Dec 09 05:23 PM
LIPPS RANDALL AChairman, President and CEODec 09Sale121.8525,0003,046,241152,116Dec 09 05:23 PM
LIPPS RANDALL AChairman, President and CEODec 08Option Exercise0.0017,5000168,965Dec 08 04:53 PM
LIPPS RANDALL AChairman, President and CEODec 08Sale110.5617,5001,934,718152,116Dec 08 04:53 PM
LIPPS RANDALL AChairman, President and CEONov 23Option Exercise0.0012,6000164,716Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 23Sale105.4012,6001,328,030152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Option Exercise0.002,4000154,516Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Sale105.012,400252,034152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 04Sale89.5911,4351,024,439229,113Nov 04 05:48 PM